Company to Webcast Presentation on February 13

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 31, 2008--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Wednesday, February 13, 2008 at 11:45 am (ET) at the Waldorf Astoria Hotel in New York.

In addition, James Barsoum, Ph.D., Senior Vice President, Research, Synta Pharmaceuticals will be presenting as a panelist in the BIO CEO therapeutic workshop Novel Cancer MOA: "New Cancer-Killing Mechanisms" at 9:30 am (ET) on February 13. Dr. Barsoum will discuss oxidative stress induction as a new therapeutic approach to treating cancer.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com. The panel will not be webcast.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit www.syntapharma.com.

    CONTACT: Synta Pharmaceuticals Corp.
             Rob Kloppenburg, 781-541-7125
             or
             MacDougall Biomedical Communications
             Doug MacDougall, 508-647-0209

    SOURCE: Synta Pharmaceuticals Corp.